Rentschler Fill Solutions GmbH entered a collaboration with Ultragenyx Pharmaceutical, Inc. for the drug product production of the injectable Mepsevii (vestronidase alfa), a recombinant form of the human enzyme beta-glucuronidase, to treat patients with mucopolysaccharidosis (MPS) VII, a rare genetic disorder.   Mepsevii was developed by U.S.-based Ultragenyx in collaboration with Rentschler Biopharma SE in Germany, and was approved by the U.S. FDA in November 2017. Ultragenyx has also applied...